Alkermes plc Ordinary Shares ALKS
i
Market dataready · fetched 2026-11-06T22:44:18.475Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:02.233137922Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-06T22:44:17.432640+00:00
Alkermes plc Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 41.35 | 93.6% | 12.9% | |||
| 30Δ | 42.38 | 96.4% | 11.6% | |||
| 35Δ | 44.27 | 58.7% | 6.4% | |||
| 40Δ | 44.96 | 58.0% | 5.5% | |||
| 45Δ | 46.60 | 43.1% | 4.3% | 45.65 | 65.4% | 5.3% |
| 50Δ | 46.15 | 45.6% | 3.9% | 46.37 | 67.9% | 4.8% |
| 55Δ | 45.69 | 43.9% | 3.3% | 47.07 | 64.7% | 3.9% |
| 60Δ | 45.24 | 40.3% | 2.6% | 47.57 | 58.4% | 3.0% |
| 65Δ | 44.76 | 38.8% | 2.0% | 48.14 | 53.6% | 2.2% |
| 70Δ | 44.25 | 39.6% | 1.7% | 49.03 | 56.8% | 1.8% |
| 75Δ | 43.57 | 42.6% | 1.4% | 50.04 | 59.0% | 1.5% |
| 80Δ | 42.82 | 45.3% | 1.2% | 52.32 | 68.4% | 1.2% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 41.35
- IV
- 93.6%
- B/E move
- 12.9%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 42.38
- IV
- 96.4%
- B/E move
- 11.6%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 44.27
- IV
- 58.7%
- B/E move
- 6.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 44.96
- IV
- 58.0%
- B/E move
- 5.5%
45Δ
- Pseudo strike
- 46.60
- IV
- 43.1%
- B/E move
- 4.3%
- Pseudo strike
- 45.65
- IV
- 65.4%
- B/E move
- 5.3%
50Δ
- Pseudo strike
- 46.15
- IV
- 45.6%
- B/E move
- 3.9%
- Pseudo strike
- 46.37
- IV
- 67.9%
- B/E move
- 4.8%
55Δ
- Pseudo strike
- 45.69
- IV
- 43.9%
- B/E move
- 3.3%
- Pseudo strike
- 47.07
- IV
- 64.7%
- B/E move
- 3.9%
60Δ
- Pseudo strike
- 45.24
- IV
- 40.3%
- B/E move
- 2.6%
- Pseudo strike
- 47.57
- IV
- 58.4%
- B/E move
- 3.0%
65Δ
- Pseudo strike
- 44.76
- IV
- 38.8%
- B/E move
- 2.0%
- Pseudo strike
- 48.14
- IV
- 53.6%
- B/E move
- 2.2%
70Δ
- Pseudo strike
- 44.25
- IV
- 39.6%
- B/E move
- 1.7%
- Pseudo strike
- 49.03
- IV
- 56.8%
- B/E move
- 1.8%
75Δ
- Pseudo strike
- 43.57
- IV
- 42.6%
- B/E move
- 1.4%
- Pseudo strike
- 50.04
- IV
- 59.0%
- B/E move
- 1.5%
80Δ
- Pseudo strike
- 42.82
- IV
- 45.3%
- B/E move
- 1.2%
- Pseudo strike
- 52.32
- IV
- 68.4%
- B/E move
- 1.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 44.73% | |
| 45.81% | |
| 47.02% | |
| 45.39% | |
| 49.86% | |
| 51.46% | |
| 51.26% | |
| 48.64% | |
| 43.67% | |
| 46.96% | |
| 46.39% | |
| 43.24% | |
| 37.66% | |
| 44.00% | |
| 48.90% | |
| 49.97% | |
| 58.83% | |
| 54.76% | |
| 52.02% | |
| 52.75% | |
| 59.76% | |
| 57.64% | |
| 58.38% | |
| 57.41% | |
| 58.76% | |
| 68.95% | |
| 63.94% | |
| 55.78% | |
| 54.04% | |
| 52.77% | |
| 53.32% | |
| 51.74% | |
| 56.57% | |
| 49.15% | |
| 56.70% | |
| 55.86% | |
| 56.86% | |
| 52.39% | |
| 53.55% | |
| 54.20% | |
| 52.36% | |
| 57.42% | |
| 54.32% | |
| 57.59% | |
| 55.52% | |
| 65.51% | |
| 76.96% | |
| 49.73% | |
| 50.85% | |
| 47.30% | |
| 48.03% | |
| 48.09% | |
| 51.37% | |
| 51.74% | |
| 51.75% | |
| 50.66% | |
| 49.92% | |
| 52.69% |
Drug Manufacturers - Specialty & Generic
AMLX
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly…
More →AMPH
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal…
More →AMRX
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic…
More →ANIK
Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
More →ANIP
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and…
More →AQST
Description unavailable
More →